MyoGene Bio Receives Venture Philanthropy and Angel Investment

November 4, 2025

MyoGene Bio is pleased to report investment from angel investors and Duchenne patient foundation venture philanthropy groups totaling $1.42M. We are very grateful for their support to advance our gene editing therapy for Duchenne and appreciate the validation and resources these groups bring to MyoGene. 

Read more here: 

https://www.duchenneuk.org/duchenne-uk-awards-500000-to-accelerate-development-of-gene-editing-therapy-for-dmd/ 

 https://www.prnewswire.com/news-releases/ppmd-provides-400-000-in-funding-to-myogene-bio-through-ppmd-venture-pathways-program-to-support-development-of-gene-editing-platform-302604220.html